Norgine enters into a new partnership with Adacyte Therapeutics to commercialise ADACOLUMN® in Switzerland

06 March 2019




Amsterdam, Wednesday 6 March, 10.00 CET. Norgine B.V. today announced that it has entered into a new partnership with Adacyte Therapeutics S.L. to exclusively distribute ADACOLUMN® in Switzerland.

ADACOLUMN® is a Class IIb CE marked medical device used as a treatment for steroid-dependant and steroid refractory moderate to severe inflammatory bowel disease (IBD).

Inflammatory bowel disease (IBD) is an umbrella term used to describe disorders that involve chronic inflammation of the digestive tract. Types of IBD include ulcerative colitis (UC) and Crohn’s disease (CD). Both UC and CD usually involve severe diarrhoea, abdominal pain, rectal bleeding, fatigue and weight loss. IBD can be debilitating and sometimes leads to life-threatening complications.[i]

Peter Martin, Chief Operating Officer at Norgine said: “We are delighted to enter into our new collaboration with Adacyte. ADACOLUMN® provides an important alternative treatment option for patients who suffer from IBD.”

Antoni Villaró,  Chief Executive Officer  of Adacyte said: “As an established leader in providing innovative gastroenterology disease solutions to patients in Europe, Norgine is an excellent partner for Adacyte and ADACOLUMN®. Norgine´s commercial track record across Europe demonstrates their ability to achieve commercial success in Switzerland and will enable the patients suffering with moderate-severe inflammatory bowel disease to receive the benefits of ADACOLUMN®.”

Norgine anticipates launching ADACOLUMN® in Switzerland in the 2nd quarter of 2019.  


Notes to Editors:

About Norgine

Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2017, Norgine’s total net sales were EUR 345 million, up 17 per cent.

Norgine employs over 1,000 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sale and supply. Norgine specialises in gastroenterology, hepatology, cancer and supportive care.

Norgine is headquartered in the Netherlands.

For more information, please visit

In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit

NORGINE and the sail logo are trademarks of the Norgine group of companies.


About Adacyte Therapeutics

Adacyte Therapeutics is a specialty therapeutic medical device company focused on the development and commercialization of innovative therapies for the treatment of difficult-to -treat autoimmune diseases mainly focused in Inflammatory Bowel Diseases. Adacyte’s lead product is ADACOLUMN®, a unique medical device system for selective leucocyte apheresis. Adacyte is a company headquartered in Barcelona, Spain and is the exclusive partner of Japan Immunoresearch Laboratories Company Limited (JIMRO) in Europe.



Inflammatory Bowel Disease is living a new era of treatment thanks to the introduction of biologic therapy. There is, however, an urgent need for therapies for steroid-dependent and steroid refractory moderate-to-severe active Inflammatory Bowel Disease patients due to side effects, patient intolerance to existing treatments and failure of previous treatments. After the failure of existing therapies, surgery is often the only remaining option. In this context, ADACOLUMN®, a Granulocyte-Monocyte Adsorptive Apheresis, is an important non-pharmacological treatment with very few side effects. ADACOLUMN®  is currently available in Europe (Germany, UK, France, Italy, Spain, Sweden, Norway, Denmark, Finland, Iceland), Japan and China.


Media Contacts:

For Norgine:

Eleni Fistikaki +44 (0)1895826227 or +44 (0)7825 389477

Clara Bentham +44 (0)1895 826654 or +44 (0)7734 367883

Follow us on twitter @norgine

For Adacyte:

Antoni Villaró, CEO, +34 618234445


[i] Crohn’s & Colitis Foundation. Diagnosing and managing IBD. 2017; 1–37. Available at: (Accessed March 2019).